B
FUSN

Braidwell’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Braidwell’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,000,000
Closed -$6.3M – 99
2022
Q4 		$6.3M Buy
+2,000,000
New +$4.98M 0.21% 83

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Braidwell's FUSN Position: Q1 2023 in Review

Braidwell sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2023, closing a stake of 2,000,000 shares — an estimated $6.3M sold.

Braidwell first reported a position in FUSN in Q4 2022 and held it in 1 quarter. The position peaked at $6.3M in Q4 2022. 38 funds tracked by Wall St. Rank hold FUSN as of Q1 2023.

  • Braidwell reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2023 after selling out during the quarter.
  • Braidwell sold 2,000,000 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2023, an estimated $6.3M.
  • Braidwell first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2022 and held it in 1 quarter.
  • Braidwell's Fusion Pharmaceuticals Inc. Common Shares position peaked at $6.3M in Q4 2022.
  • 38 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2023.

Based on Braidwell's 13F filing for Q1 2023, filed 15 May 2023.